The invention relates to compounds of formula (I) wherein R1 is hydrogen or lower alkyl R2 is hydrogen or is heteroaryl, optionally substituted by one or more halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl R3 is hydrogen, halogen, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen, cyano, S-lower alkyl, S(O)-lower alkyl, S(O)2-lower alkyl, C(O)-lower alkyl or C3-6-cycloalkyl R4 is hydrogen or lower alkyl (A) is phenyl or pyridinyl, wherein the N-atom may be in different positions X is a bond or CH(CF3)- Ar is aryl or heteroaryl, optionally substituted by one or more R3 or to a pharmaceutically suitable acid addition salt thereof. It has now been found that the compounds of formula I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinsons disease, neurodegenerative disorders such as Alzheimers disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm and cardiovascular disorders.La présente invention concerne des composés de formule (I) où R1 représente un atome dhydrogène ou un groupement alkyle court R2 représente un atome dhydrogène ou un groupement hétéroaryle, éventuellement substitué par un ou plusieurs atomes dhalogène ou groupements alkyle court, alkyle court halogéné, alkoxy court, alkoxy court halogéné, cyano, S-alkyl
